Side-by-side · Research reference
CrystagenvsHCG
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-MechanisticHUMAN-REVIEWED12/40 cited
BFDA-ApprovedHUMAN-REVIEWED12/52 cited
Crystagen
Khavinson Bioregulator · Immune-Thymic
SQ · Protocol variable
HCG
Glycoprotein Hormone · LH Mimetic
IM or SQ · 2–3×/week
01Mechanism of Action
Parameter
Crystagen
HCG
Primary target
B-lymphocytes in splenic tissueСhervyakova 2014
LH receptors on testicular Leydig cellsSchröder-Lange 2025
Pathway
B-cell activation → Immune modulation during agingСhervyakova 2014
hCG → Leydig cell LH receptor → Intracellular cAMP → Steroidogenesis pathway activation → Testosterone synthesis
Downstream effect
B-cell activation via apoptosis reduction; no observed increase in splenic cell renewalСhervyakova 2014
Elevated intratesticular testosterone, restored spermatogenesis, virilization, secondary sex characteristic developmentKonsam 2026Zachariou 2026
Feedback intact?
Unknown — bioregulator mechanism not fully characterized
No — exogenous hCG bypasses hypothalamic-pituitary axis; endogenous LH remains suppressed
Origin
Synthetic Lys-Glu-Asp-Gly tetrapeptide — Khavinson bioregulator series
Heterodimeric glycoprotein (alpha subunit shared with LH/FSH/TSH; beta subunit confers specificity). Available as urinary-derived or recombinant formulations.
Antibody development
—
Rare with recombinant; possible with urinary-derived formulations
02Dosage Protocols
Parameter
Crystagen
HCG
Standard dose
Not standardized — variable protocols
Russian bioregulator literature does not specify unified human dosing.
—
Frequency
Unknown — bioregulator protocols variable
—
Duration
Unknown — chronic administration presumed in animal models
—
Half-life
Not reported
—
Hypogonadotropic hypogonadism (monotherapy)
—
2,000 IU IM/SQ 2–3×/weekKonsam 2026Zachariou 2026
Titrate to normalize testosterone (300–1,000 ng/dL) or achieve target AMH ~7.4 ng/mL.
Combined therapy (hCG + FSH)
—
hCG 2,000 IU 2×/wk + rFSH 75 IU 3×/wkKonsam 2026Nariyoshi 2025
Preferred for azoospermia; FSH added after initial hCG phase or from outset.
Triple therapy (experimental)
—
hCG 2,000 IU 2×/wk + rFSH 75 IU 3×/wk + testosterone 100 mg IM q2wkKonsam 2026
May accelerate virilization; reduces hCG requirements (~30% lower cumulative dose vs monotherapy).
Cryptorchidism (pediatric)
—
500–4,000 IU IM 2–3×/week for 3–6 weeks
Duration to sperm appearance
—
12–24 months (median ~18 mo)Huijben 2026Zachariou 2026
Congenital HH may require longer treatment; acquired HH responds faster.
Monitoring
—
Serum testosterone, semen analysis q3–6mo, testicular ultrasound
Thickened seminiferous tubules (>300 μm) on ultrasound predict imminent sperm appearance.Nariyoshi 2025
04Side Effects & Safety
Parameter
Crystagen
HCG
Published adverse events
None reported in available animal literature
—
Human safety data
Absent — no controlled human trials identified
—
Autoimmune considerations
Theoretical concern with B-cell modulators in predisposed individuals
—
Injection site reaction
—
Pain, erythema (mild, transient)
Gynecomastia
—
Aromatization of elevated testosterone to estradiol; dose-dependent
Testicular discomfort / Edema
—
Rapid testicular growth in hypogonadal males; usually self-limiting
Polycythemia
—
Elevated hematocrit from supraphysiological testosterone; monitor CBC
Mood / Libido changes
—
Variable; usually positive with normalization of testosterone
Acne / Oily skin
—
Androgen-mediated; dose-dependent
Prostate concerns
—
Monitor PSA in older males; hCG restores physiological testosterone (not supraphysiological)
Antibody formation
—
Rare with recombinant; possible with urinary-derived
Absolute Contraindications
Crystagen
- ·Active autoimmune disease (theoretical)
HCG
- ·Androgen-dependent malignancy (prostate, breast cancer)
- ·Hypersensitivity to hCG or excipients
- ·Precocious puberty
Relative Contraindications
Crystagen
- ·Pregnancy / lactation (no data)
- ·Active B-cell malignancies
HCG
- ·Untreated obstructive sleep apnea
- ·Severe cardiovascular disease (polycythemia risk)
- ·History of thromboembolism
05Administration Protocol
Parameter
Crystagen
HCG
1. Route
Subcutaneous injection — presumed from bioregulator class convention. Specific anatomical sites not standardized.
Add sterile water or bacteriostatic water per manufacturer instructions. Typically 1–2 mL per 5,000–10,000 IU vial. Roll gently — do not shake. Solution should be clear.
2. Reconstitution
Protocol not standardized. If lyophilized, sterile water or bacteriostatic saline typical for peptide bioregulators.
Intramuscular: ventrogluteal, vastus lateralis, or deltoid. Subcutaneous: abdomen, avoiding navel (2-inch radius). Rotate sites to prevent lipohypertrophy.
3. Timing
Not specified. Bioregulator protocols vary — some practitioners advocate evening dosing, others morning.
Administer 2–3 times per week. Consistent weekly schedule recommended (e.g., Monday/Thursday or Monday/Wednesday/Friday).
4. Storage
Lyophilized: room temperature, light-protected. Reconstituted: refrigerate, use within days to weeks depending on preservative.
Lyophilized: room temperature, light-protected. Reconstituted: refrigerate 2–8 °C. Bacteriostatic water extends shelf life to ~30 days; sterile water use within 72 hours.
5. Needle selection
—
IM: 21–23G, 1–1.5 inch. SQ: 25–27G, 5/8 inch. Inject slowly (30–60 seconds for IM).
06Stack Synergy
Crystagen
+ Vilon
Multi-pathwayVilon (Lys-Glu) activates T-helper cells via apoptosis reduction, while Crystagen activates B-cells. Dual T/B immune modulation in aging models may provide complementary thymic-immune support within the Khavinson bioregulator framework. Both target splenic immune aging through distinct lymphocyte subsets.
- Crystagen
- Dose unknown · SQ
- Vilon
- Dose unknown · SQ
- Frequency
- Protocol variable
- Primary benefit
- Broader thymic-immune coverage (T-cell + B-cell)
HCG
— no documented stacks